Market Overview

Retrophin to Present at the 35th Annual J.P. Morgan Healthcare Conference

Share:

SAN DIEGO, Dec. 29, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that Stephen Aselage, chief executive officer, will present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 12, 2017 at 10:30 a.m. PT.

A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm  and an archived replay will be accessible for up to 90 days.
           
About Retrophin

Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products Thiola®, Cholbam® and Chenodal®.

Retrophin.com

Contact: Chris Cline, CFA Senior Director, Investor Relations 646-564-3680 IR@retrophin.com

Primary Logo

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com